Fig. 1

eEF2K inhibition promotes lung cancer cell proliferation of and alleviates the effects of gefitinib. a A549 cells were transfected with the indicated plasmids. Immunoblotting analyses were performed with the indicated antibodies. b A549 cells with or without eEF2K depletion or overexpression were cultured for the indicated periods of time. MTT assay was performed. n = 5. *P < 0.05, **p < 0.01, vs shNC or Ctrl. c A549 cells with or without eEF2K depletion were cultured for 15 days, fixed with methanol, and then stained with Giemsa. The clone numbers were counted under microscope. n = 3. **p < 0.01, vs shNC. d, e A549 cells with or without eEF2K depletion were cultured in glucose-deprived medium (d) or serum-deprived medium (e). The cell proliferation was examined by MTT assay. n = 5. *P < 0.05, **p < 0.01, vs shNC. ^##p < 0.01, vs sheEF2K (48 h or 24 h). f A549 cells were treated with Gefitinib at the indicated concentrations. Immunoblotting analyses were performed with the indicated antibodies. g A549 expressing with or without eEF2K siRNA were treated with Gefitinib at the indicated concentrations. Immunoblotting analyses were performed with the indicated antibodies. The cell viabilities were determined by MTT assay, The histogram shows the percentages of the viable cells. *P < 0.05, **p < 0.01, vs SiNC. (H) A549 cells with or without eEF2K depletion were treated with or without CHX. The cell proliferation were determined by MTT assay. *P < 0.05, **p < 0.01, vs no treated CHX. ^#P < 0.05,^##P < 0.01, vs shNC. ^ΔΔP < 0.01, vs shNC+CHX. i-j A549 cells with or without eEF2K depletion or overexpression were cultured in serum-free medium for 12 h followed by complete medium for 12 h. The culture medium and cell lysate were examined for lactate secretion (i), glucose amount in medium (j). **P < 0.01, vs shNC. ^#P < 0.05, ^##P < 0.01, vs Ctrl